Aluminum-Phthalocyanine Chloride-Based Photodynamic Therapy Inhibits PI3K/Akt/Mtor pathway in Oral Squamous Cell Carcinoma Cells

Nathália Vieira Velloso, Luis Alexandre Muehlmann*, João Paulo Figueiró Longo, Jaqueline Rodrigues da Silva, Daniela Cervelle Zancanela, Antônio Cláudio Tedesco and Ricardo Bentes de Azevedo

1Department of Genetics and Morphology, Institute of Biology, University of Brasília, Brasília DF 70910-900, Brazil
2Nanodynamics Consulting and Innovation Ltd., Brasilia/DF, 70910-900, Brazil
3Department of Chemistry, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto – USP, Ribeirão Preto, Brazil

Abstract

The present study investigated the in vitro effects of liposomal aluminum-phthalocyanine chloride (AlPc)-based Photodynamic Therapy (PDT) on PI3K/Akt/mTOR signaling pathway, which has been reported to be constantly activated in squamous cell carcinoma. Cultured cells derived from Oral Squamous Cell Carcinoma (OSCC-3 lineage) were used. PDT was applied in vitro by exposing cultured cells to liposomal AlPc (0.5 or 2.5 µM for 30 minutes) and then irradiating them with laser (670 nm wavelengths, 24 J/cm² energy density). Cell viability was assessed by tripan blue staining and MTT assay. DNA fragmentation and mitochondrial permeability, signs of apoptosis, were also evaluated. Inhibition of PI3K/Akt/mTOR was accessed by immunofluorescence assay for detection of pS6, a downstream phosphorylated protein of this signaling pathway, in confocal microscopy. Morphological analysis was performed by FACS scan and phase contrast microscopy. Different mechanisms of cell death were induced in OSCC-3 cells, mainly apoptosis. Moreover, PI3K/Akt/mTOR signaling pathway was inhibited. The results show that cell death induced by AlPc-based PDT involves, at least partially, inhibition of the PI3K/Akt/mTOR pathway.

Keywords: Photodynamic therapy; Oral cancer; Cell death; mTOR, PI3K/Akt/mTOR pathway

Introduction

Human Oral Squamous Cell Carcinoma (OSCC) is a highly incident disease associated to several risk factors. Its treatment is usually associated with the risk of serious cosmetic or functional morbidity, mainly when surgery or radiotherapy is the mainline treatment [1,2]. Therefore, there is a need for therapeutic alternatives that preserve the normal architecture and function of the treated area and achieve tumor control comparable to or better than that obtained with classical therapies [3]. In this context, Photodynamic Therapy (PDT) has been shown to be a good candidate for treating OSCC. It involves reactions induced by light activation of a photosensitizer, namely type I and type II photoreactions (see figure 1) [4]. Both photoreactions generate oxidant species that affect cell structure and function, causing alterations in the cell itself, in its microenvironment and even in the whole organism. Type II photoreactions are generally more pronounced in PDT, since the light-activated photosensitizer catalyzes the triplet-to-singlet conversion of thousands of oxygen molecules; singlet oxygen has a markedly higher oxidant potential in comparison to triplet oxygen [5].

Some researchers have found that some specific molecular targets and organelles can be affected by PDT, profoundly influencing the fate of a PDT-treated cell and the effectiveness of the anticancer PDT itself [6]. The result depends mainly on the photosensitizer, oxygen concentration, light dose and wavelength, and the cell genotype [6]. PDT can kill cancer cells directly by efficiently inducing apoptosis as well as by activating non-apoptotic cell death pathways [6]. It can also damage the tumor-associated blood vessels, thus contributing to tumor regression [7], and activate or boost tumor-specific immune responses [8]. On one hand, for example, certain photosensitizers, particularly the hydrophobic ones, have been shown to accumulate in the mitochondria, where they can induce apoptosis when activated by light [9]; on the other hand, photosensitizers that accumulate in the plasma membrane or in lysosomes can either delay or block apoptosis and predispose cells to death by necrosis [6]. In this context, PDT can affect molecules in certain signaling pathways involved in cell death, an event that could determine what its outcomes would be [6].

The mammalian target of rapamycin (mTOR), a 289 kDa serine/threonine kinase, located downstream of the PI3K-Akt pathway, has been shown to be a major regulator of cell growth, proliferation, migration, differentiation, and survival [10]. In many human cancers, upstream (PI3K-Akt) and downstream (4E-BP1 and S6 kinase) signaling pathways of mTOR are deregulated and hence mTOR has been suggested to be a target for suppression of tumor growth [11]. In OSCC, activation of Phosphatidylinositol 3-Kinase (PI3K) is a frequent event [6] and mTOR is thus expected to be involved in the pathophysiology of this cancer. Previous work has demonstrated that the mTOR pathway is a target for PDT when an endolysosomal localizing phthalocyanine derivative, AlPcS₂, was used [11]. As liposomal AlPc-based PDT was shown to be effective against 4-Nitroquinoline-1-Oxide (4-NQO)-induced murine oral cancer in vivo, the present study evaluated the effects of this PDT protocol on the PI3K/Akt/mTOR pathway, in vitro. The results show that AlPc-based PDT inhibits PI3K/Akt/mTOR pathway in cultured human OSCC cells.

*Corresponding author: Luis Alexandre Muehlmann, Nanodynamics Consulting and Innovation Ltd., Brasilia/DF, 70910-900, Brazil, Tel/Fax: +55 61 82174852; E-mail: luis@nanodynamics.com.br

Received October 26, 2012; Accepted November 13, 2012; Published November 16, 2012

Citation: Velloso NV, Muehlmann LA, Longo JPF, da Silva JR, Zancanela DC, et al. (2012) Aluminum-Phthalocyanine Chloride-Based Photodynamic Therapy Inhibits PI3K/Akt/mTORpathway in Oral Squamous Cell Carcinoma Cells In Vitro. Chemotherapy 1:107. doi:10.4172/2167-7700.1000107

Copyright: © 2012 Velloso NV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The viability of the cells was assayed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Invitrogen, EUA) test. This is a colorimetric assay that relies on the ability of mitochondria from viable cells to convert MTT to an insoluble formazan, causing a yellow-to-purple color change. Briefly, twenty-four hours after treatment, medium was renewed, 20 µL 10% (w/v) MTT solution were added to each well and the cells were then incubated for 3 h at culture conditions. Then, medium was removed, formazan was extracted from cells with 150 µL of dimethyl sulfoxide (Sigma, St Louis, MO) and absorbance at 595 nm was measured with a spectrophotometer (Spectra MAX M2– Molecular Devices).

**Morphological analysis**

Morphological analysis was based on two methods: FACS scan and phase contrast microscopy. For FACS, 24 h after the treatment, the floating and adherent cells were harvested, centrifuged, washed with 500 µL PBS and resuspended in 100 µL PBS. Next, cell granularity and volume were both measured by FACSscan (FACS-Calibur, Becton Dickinson) flow cytometry and analyzed by CellQuest software. For phase contrast microscopy, 24 h after treatment, cells were analyzed using an inverted phase contrast microscope (Unico, EUA).

**Measurement of mitochondrial membrane potential**

Cytotluorometry was used to detect cellular cytotoxic effects, as described elsewhere [13]. For this assay, it was used rhodamine 123, a cationic fluorescent dye that penetrates into the cell and accumulates in mitochondria. Rhodamine effluxes from mitochondria when the membrane potential of this organelle is reduced, lowering the fluorescence of the cell. Briefly, 24 h after treatments, the floating and adherent cells were harvested, centrifuged, washed with 500 µL PBS and resuspended in 100 µL PBS. Next, cells were incubated with 0.5 µL solution of rhodamine 123 (5 mg/mL in ethanol) (Invitrogen, USA). After 15 minutes of incubation at room temperature, protected from light, cells were washed twice with 500 µL PBS. After each wash the samples were centrifuged (750xg for 3 minutes) and the supernatants were discarded. Next, cells were incubated for 30 minutes in 300 µL of PBS at room temperature, protected from light. Then, samples were evaluated using a FACSscan flow cytometry (FACS-Calibur, Becton Dickinson) at FL1-H (515-530 nm) and analyzed by the CellQuest software.

**Detection of DNA fragmentation using FACS**

This protocol is based on the fact that Propidium Iodide (PI) binds DNA allowing for measuring cell DNA content [14]. Briefly, 24 h after treatment, the floating and adherent cells were harvested, centrifuged and resuspended in 100 µL PBS. For DNA fragmentation analysis, 200 µL PI-containing buffer (0.1% (w/v) sodium citrate, 0.1% (w/v) Triton X-100 and 20 µg/mL PI) (Invitrogen, USA) were added and the mixture was then incubated for 30 minutes in the dark, at room temperature. Next, samples were evaluated using a FACSscan flow cytometry (FACS-Calibur, Becton Dickinson) at FL2-H (560-580 nm) and analyzed by the CellQuest software.

**Immunofluorescence detection of pS6**

For immunofluorescence, a laser scanning confocal fluorescence microscope was used as previously reported [15]. This experiment was performed with groups control, L-AlPc 2.5 µM and PDT 2.5 µM. Cells were cultured on polyllysine coated coverslips. Twenty four hours after the treatments, cells were washed, fixed with 2% (w/v) paraformaldehyde and analyzed by the CellQuest software.
(Vetec Quimica Fina, Brazil) at room temperature for 10 minutes, washed with PBS and permeabilized with 0.2% (w:v) Triton X-100 for 10 minutes. Next, cells were washed with PBS, incubated with a blocking solution (2% (w:v) BSA and 5% (w:v) goat serum) for 30 minutes and incubated with the first primary antibody (ribosomal pS6, ser 240/244, Cell Signaling, USA) diluted 1:20 in blocking solution overnight at 4°C. After washing, slides were sequentially incubated for 2 h with the secondary antibody (rabbit anti-IgG FITC-Cell Signaling, USA) diluted 1:300, followed by washes with PBS. The slides were then mounted with 4',6-diamidino-2-phenylindole (Sigma-Aldrich Co., USA) and images were captured with a confocal microscope (Leica TCS SP5, USA).

**Statistically analyses**

Data were analyzed by ANOVA one way followed by Tukey multiple comparison tests (α=0.05). Data analysis was performed with GraphPad Prism version 5.00 for Windows.

**Results**

**Liposomal AlPc-based PDT reduces OSCC-3 cells viability in vitro**

The first step in this work was to investigate if liposomal AlPc-based PDT reduces the viability of OSCC-3 cells in vitro. Figure 2a shows the results obtained for cell viability by MTT assay. At 0.5 and 2.5 µM AlPc, in the dark, a decrease of c.a. 30% in the viability of OSCC-3 cell occurred. When cells exposed to liposomal AlPc were irradiated, a further statistically significant, AlPc dose-dependent decrease in cell viability was observed (c.a. 50% for 0.5 µM and 75% for 2.5 µM). The number of viable cells, as assessed by trypan blue staining assay (figure 2b), significantly decreased only in cells treated with PDT at 2.5 µM AlPc (c.a. 45% lower vs control).

**Morphology of OSCC-3 is altered by liposomal AlPc-based PDT**

Alterations in cell shape and an increase in the number of detached cells were observed under phase contrast microscopy on PDT groups in a dose-dependent manner in comparison to control group, as shown in figure 3a. Alterations in cell volume and cytoplasm granulosity (Figure 3c) were also observed in PDT groups. Figure 4a shows an AlPc dose-dependent decrease in mitochondrial membrane potential (∆Ψm) in PDT groups (15% PDT 0.5 µM and PDT 2.5 µM 23% vs control, p<0.05). Moreover, DNA fragmentation was intense in cells of PDT 0.5 and 2.5 µM group, although this event was also observed in cells treated with liposomal AlPc in the dark.

**Liposomal AlPc-based PDT reduces the amount of pS6 per OSCC-3 cell**

The analysis of pS6 protein showed that cells from control group presented intense fluorescence on the cytoplasm, evidencing the presence of pS6 (Figure 5a). After application of PDT, this fluorescence was reduced, indicating an inhibition of the PI3K/Akt/mTOR pathway (Figure 5b). There was no visible difference between cells of control and L-AlPc 2.5 µM groups for the presence of pS6.

**Discussion**

The results obtained in this work show that the treatment of OSCC 3 cells with liposomal AlPc-based PDT induced a significant, dose-dependent reduction of cell viability and the number of cells 24h after its application, particularly in cells exposed to 2.5 µM AlPc. This result confirms that this liposomal formulation is effective against cancer cells, as previously demonstrated in vivo [16] and in vitro [3]. The reduced viability and number of cells after PDT treatment was paralleled by alterations on cell morphology. Under phase contrast microscopy, OSCC-3 cells treated with PDT, at both 0.5 µM and 2.5 µM AlPc, presented lower adhesion to the culture plate when compared to control cells. The analysis using flow cytometry showed reduction in volume and in quantity of cell granules in OSCC-3 cells of the PDT 2.5 µM group. These evidences suggested that cells could be undergoing an apoptotic process induced by PDT [3].

In fact, evidences indicate that PDT can directly kill the cancer cells by the induction of apoptosis, necrosis or the autophagy [6]. The next
step in this work was to investigate if PDT induced apoptosis in OSCC-3 cells. In this context, mitochondria are increasingly recognized as an important target organelle during photo damage to tumor cells [17]. Many hydrophobic photosensitizers, such as AlPc itself, localize in mitochondria membranes where they can trigger apoptosis. This event is typically observed just after PDT application and is followed by the apoptosome-mediated caspase activation cascade [18]. As previously observed, during PDT-mediated apoptosis, mitochondrial membrane potential progressively collapses due to a lack of membrane selective permeability [18]. Reduced mitochondrial membrane potential was, in fact, observed in this study with OSCC-3 cells submitted to PDT with both AlPc concentrations tested. This result suggests that liposomal AlPc-based PDT induces apoptosis in OSCC-3 cells. DNA fragmentation, another sign of apoptosis [19], was also induced by PDT, particularly at 2.5 µM AlPc. The liposomal formulation itself, in the dark, induced significant DNA fragmentation, but it was lower in comparison to PDT groups.

PDT is known to induce oxidative stress and induce apoptosis both in vitro and in vivo [5]. Multiple signaling pathways are involved in PDT-induced cell death. In mammals, one of the main pathways involved in apoptosis control is the PI3K/Akt/mTOR pathway [1]. In the present work the inhibition of the PI3K/Akt/mTOR pathway was evaluated through immunofluorescence for the detection of the phosphorylated protein, downstream of mTOR, pS6 [4]. The present study shows that PDT with 2.5 µM AlPc reduced the amount of pS6 per cell. This result can support further investigations on how PDT affects cell signaling pathways and how it influences the fate of a treated cell.

Concluding, the results presented here suggest that the treatment with PDT using liposomal AlPc triggers apoptosis in OSCC-3 cells, an event that may be related to an inhibition of PI3K/Akt/mTOR signaling pathway. Further studies on how PDT can affect this and other pathways affecting cell death may be useful for improving PDT protocols. Photosensitizer molecules and formulations may be designed to affect specific molecules or organelles in a target cell to enhance PDT effectiveness. This may be the future of modern PDT.

Acknowledgements

Financial support from the Brazilian agencies MCT/CNPq, FINEP, CAPES, FAP-DF, and FINATEC is gratefully acknowledged.

References

1. Amorphophilotham P, Patel V, Sodhi A, Nikitakis NG, Sawk JJ, et al. (2005) Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65: 9953-9961.
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
3. Tapajós EC, Longo JP, Simioni AR, Lacava ZG, Santos MF, et al. (2008) In vitro photodynamic therapy on human oral keratinocytes using chloroaluminum-phthalocyanine. Oral Oncol 44: 1073-1079.
4. Bonnett R (1995) Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev 24: 19-33.
5. Macdonald JI, Thomas JD (2001) Basic principles of photodynamic therapy. J Porphyr Phthalocyanines 5: 105-129.
6. Buaalbert E, Dewaele M, Agostinis P (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776: 86-107.
7. Ben-Hur E (1992) Basic photobiology and mechanisms of action of phthalocyanines. In: Dougherty T, Henderson BW (Eds) Photodynamic Therapy. Basic Principles and Clinical Applications. Marcel Dekker, New York.
8. Castano AP, Mnoz P, Hamblin MR (2008) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6: 535-545.
9. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB (2004) Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 1704: 59-86.
10. Sun Q, Chen X, Ma J, Peng H, Wang F, et al. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isozyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108: 4129-4134.
11. Weyergang A, Berger K, Kaalhus O, Peng Q, Selbo PK (2008) Photodynamic therapy targets the mTOR signaling network in vitro and in vivo. Mol Pharm 6: 255-264.
12. Nunes SM, Sguilla FS, Tedesco AC (2004) Photophysical studies of zinc phthalocyanine and chloroaluminum phthalocyanine incorporated into liposomes in the presence of additives. Braz J Med Biol Res 37: 273-284.
13. Lecoeur H (2002) Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Exp Cell Res 277: 1-14.
14. Nunez R (2001) DNA measurement and cell cycle analysis by flow cytometry.Curr Issues Mol Biol 3: 67-70.
15. Mitra S, Foster TH (2008) In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. Neoplasia 10: 429-438.
16. Figueiró Longo J, Muehlmann L, Velloso N, Simioni A, Lozzi S (2012) Effects of Photodynamic Therapy Mediated by Liposomal Aluminum-phthalocyanine Chloride on Chemically Induced Tongue Tumors. Chemotherapy 1.
17. Nak N, Li KM, Leung WN, Wong RN, Huang DP, et al. (2004) Involvement of both endoplasmic reticulum and mitochondria in photokilling of nasopharyngeal carcinoma cells by the photosensitizer Zn-BC–AM. Biochem Pharmacol 63: 2387-2396.
18. Maftoum-Costa M, Naves KT, Oliveira AL, Tedesco AC, da Silva NS, et al. (2008) Mitochondria, endoplasmic reticulum and actin filament behavior after PDT with chloroaluminum phthalocyanine liposomal in HeLa cells. Cell Biol Int 32: 1024-1028.
19. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407: 784-789.